Erectile Dysfunction Clinical Trial
Official title:
A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer
Although the high prevalence of erectile dysfunction (ED) was detected among male patients
after the treatment for colorectal cancer, published reports depicting the erectile
dysfunction experience of patients with colorectal cancer ot underpin service development
are insufficient. Furthermore,unlike patients with prostate cancer, men with colorectal
cancer are not routinely offered information and treatment for erectile dysfunction.However,
investigations on patients after surgery for prostate cancer could provide some potentially
useful insights. The ability of sildenafil and vacuum erection device (VED) to aid in the
return of erections after nerve-sparing radical prostatectomy has been established, which
may benefit rectal cancer patients after surgery with ED.
Laparoscopic surgery, although technically demanding and associated with a long learning
curve, has the advantage of clear visualization for the smallest structures,including the
autonomic nerves. Laparoscopic resection for rectal cancer could thus facilitate
preservation of the pelvic autonomic nerves.
This study aimed to identify whether early intervention is effective at reducing the rate of
ED at 12 months.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |